Insulet Q3 2025 Earnings Report

Insulet EPS Results

• Actual EPS: N/A
• Consensus EPS: $1.15
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Insulet Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $678.70 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Insulet Announcement Details

• Quarter: Q3 2025
• Date: 11/6/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, November 6, 2025
• Conference Call Time: 7:00AM ET

Insulet (NASDAQ:PODD) is a medical technology company specializing in the design, development and commercialization of innovative insulin delivery systems for people with diabetes. The company’s flagship offering, the Omnipod Insulin Management System, is a tubeless, wearable insulin pump that combines a small, disposable Pod with a handheld Personal Diabetes Manager (PDM) or compatible smart device to automate and personalize insulin delivery. Insulet focuses on simplifying glycemic management and improving patient quality of life through intuitive device design and remote monitoring capabilities.

In addition to its original Omnipod system, Insulet has expanded its product portfolio to include the Omnipod DASH® System and Omnipod® 5 Automated Insulin Delivery System. Omnipod DASH employs Bluetooth technology to communicate with a secure, dedicated controller for on-demand insulin dosing, while Omnipod 5 integrates real-time continuous glucose monitoring (CGM) to automatically adjust insulin delivery in response to glucose readings. The company also offers digital tools such as data-sharing platforms and mobile apps that allow patients and care teams to track therapy, analyze trends and make informed treatment decisions.

Founded in 2000 and headquartered in Acton, Massachusetts, Insulet serves patients in North America, Western Europe, Australia, Japan and select other markets through a combination of direct commercial operations and strategic distribution partnerships. The company went public in 2007 and has since invested in global manufacturing and customer support infrastructure. Insulet’s leadership team is led by President and Chief Executive Officer Shacey Petrovic, who brings extensive experience in medical devices and technology commercialization. Under her direction, Insulet continues to pursue research and development initiatives aimed at expanding access to its insulin management solutions and advancing next-generation digital health offerings.